Literature DB >> 1977410

Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists.

P J Elliott1, S P Close, D M Walsh, A G Hayes, A S Marriott.   

Abstract

Subcutaneous administration of fluphenazine elicits catelepsy that can be attenuated by the glutamate antagonists MK801 and phencyclidine (PCP). 3-[-(+)-2-carboxy piperazine-4-yl]-propyl-1-phosphanate (CPP) was found to be ineffective in this model. Intrastriatal injections of sulpiride or fluphenazine were also found to induce catalepsy which could be attenuated by MK801 and PCP. These results illustrate that nondopaminergic compounds might possibly be of value in the treatment of Parkinson's disease. Furthermore it was demonstrated that this paradigm can be utilized to investigate neurotransmitter interactions within the striatum. This was clearly emphasized by the observation that bilateral administration of MK801 into the striatum increased basal locomotor activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977410     DOI: 10.1007/bf02260897

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  11 in total

1.  The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals.

Authors:  N I Rukoyatkina; L V Gorbunova; V E Gmiro; N Ya Lukomskaya
Journal:  Neurosci Behav Physiol       Date:  2003-03

2.  Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats.

Authors:  D C Hoffman
Journal:  J Neural Transm Gen Sect       Date:  1992

3.  Anticataleptic potencies of glutamate-antagonists.

Authors:  W J Schmidt; B Zadow; B D Kretschmer; W Hauber
Journal:  Amino Acids       Date:  1991-06       Impact factor: 3.520

Review 4.  Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.

Authors:  A R Braun; M Laruelle; M M Mouradian
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.

Authors:  B Zadow; W J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

6.  Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.

Authors:  A Fredriksson; C Gentsch; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Age-dependent loss of NMDA receptors in hippocampus, striatum, and frontal cortex of the rat: prevention by acetyl-L-carnitine.

Authors:  M Castorina; A M Ambrosini; L Pacific; M T Ramacci; L Angelucci
Journal:  Neurochem Res       Date:  1994-07       Impact factor: 3.996

8.  Further contribution to the study of corticostriatal glutamatergic and nigrostriatal dopaminergic interactions within the striatal network: an in vivo voltammetric investigation.

Authors:  C Forni; N Dusticier; A Nieoullon
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

9.  The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.

Authors:  B D Kretschmer; B Zadow; T L Volz; L Volz; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1992

10.  Discrete quinolinic acid lesions of the lateral but not of the medial caudate-putamen reversed haloperidol-induced catalepsy in rats.

Authors:  W Hauber; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.